S&P 500   2,996.66 (+0.02%)
DOW   26,764.43 (-0.09%)
QQQ   191.70 (-0.08%)
AAPL   242.47 (+1.05%)
FB   185.69 (+1.84%)
MSFT   136.23 (-0.11%)
GOOGL   1,254.61 (+1.08%)
AMZN   1,761.06 (-0.26%)
NVDA   193.60 (-1.03%)
MU   44.57 (-0.20%)
BABA   169.23 (-0.39%)
TSLA   254.24 (-0.52%)
AMD   31.31 (-0.63%)
T   37.70 (-1.23%)
ACB   3.68 (+2.51%)
BAC   31.34 (+0.45%)
GILD   66.49 (+0.94%)
S&P 500   2,996.66 (+0.02%)
DOW   26,764.43 (-0.09%)
QQQ   191.70 (-0.08%)
AAPL   242.47 (+1.05%)
FB   185.69 (+1.84%)
MSFT   136.23 (-0.11%)
GOOGL   1,254.61 (+1.08%)
AMZN   1,761.06 (-0.26%)
NVDA   193.60 (-1.03%)
MU   44.57 (-0.20%)
BABA   169.23 (-0.39%)
TSLA   254.24 (-0.52%)
AMD   31.31 (-0.63%)
T   37.70 (-1.23%)
ACB   3.68 (+2.51%)
BAC   31.34 (+0.45%)
GILD   66.49 (+0.94%)
Log in

GW Pharmaceuticals PLC- Stock Price, News & Analysis (NASDAQ:GWPH)

$128.44
+4.09 (+3.29 %)
(As of 10/23/2019 03:10 PM ET)
Today's Range
$123.70
Now: $128.44
$130.49
50-Day Range
$108.42
MA: $125.72
$150.42
52-Week Range
$90.14
Now: $128.44
$196.00
Volume422,859 shs
Average Volume794,730 shs
Market Capitalization$3.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.23
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.74 million
Book Value$22.23 per share

Profitability

Net Income$-295,160,000.00
Net Margins-101.45%

Miscellaneous

Employees791
Market Cap$3.97 billion
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.


GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.74) by $0.96. The biopharmaceutical company earned $72.04 million during the quarter, compared to analyst estimates of $37.28 million. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. The business's revenue was up 2096.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.25) EPS. View GW Pharmaceuticals PLC-'s Earnings History.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for GW Pharmaceuticals PLC-.

How can I listen to GW Pharmaceuticals PLC-'s earnings call?

GW Pharmaceuticals PLC- will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for GWPH?

12 equities research analysts have issued twelve-month price objectives for GW Pharmaceuticals PLC-'s stock. Their predictions range from $185.00 to $238.00. On average, they anticipate GW Pharmaceuticals PLC-'s stock price to reach $215.00 in the next twelve months. This suggests a possible upside of 67.7% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

What is the consensus analysts' recommendation for GW Pharmaceuticals PLC-?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

What are Wall Street analysts saying about GW Pharmaceuticals PLC- stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC- stock:
  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (10/18/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating on GW Pharmaceuticals and raising our 12-month price target to $196/ADS from $193/ ADS following the announced sale of Voucher (PRV). As a reminder, GW Pharmaceuticals was awarded the PRV following the EPIDIOLEX approval last year. The recipient of the PRV was not announced in the press release." (3/18/2019)

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

Media headlines about GWPH stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for GW Pharmaceuticals PLC-.

Are investors shorting GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,470,000 shares, an increase of 12.6% from the August 30th total of 3,970,000 shares. Based on an average daily volume of 577,800 shares, the days-to-cover ratio is presently 7.7 days. Approximately 14.6% of the company's stock are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

What other stocks do shareholders of GW Pharmaceuticals PLC- own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), GW Pharmaceuticals (GWP), Netflix (NFLX), Cronos Group (CRON), Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA) and Aurora Cannabis (ACB).

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the folowing people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
  • Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)

Who are GW Pharmaceuticals PLC-'s major shareholders?

GW Pharmaceuticals PLC-'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rothschild Investment Corp IL (0.06%), Lake Street Financial LLC (0.02%), Henry James International Management Inc. (0.02%), Foundry Partners LLC (0.02%), North Star Investment Management Corp. (0.01%) and Stephens Inc. AR (0.01%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

Which major investors are selling GW Pharmaceuticals PLC- stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Prospera Financial Services Inc, Exane Derivatives, Coastal Investment Advisors Inc., Envestnet Asset Management Inc. and Financial Gravity Wealth Inc.. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

Which major investors are buying GW Pharmaceuticals PLC- stock?

GWPH stock was acquired by a variety of institutional investors in the last quarter, including North Star Investment Management Corp., Henry James International Management Inc., Enlightenment Research LLC, Rothschild Investment Corp IL, Stephens Inc. AR, Squar Milner Financial Services LLC, Lake Street Financial LLC and Valeo Financial Advisors LLC. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $128.17.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $3.96 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-295,160,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


MarketBeat Community Rating for GW Pharmaceuticals PLC- (NASDAQ GWPH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  669 (Vote Outperform)
Underperform Votes:  403 (Vote Underperform)
Total Votes:  1,072
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC- and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Operating Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel